-+ 0.00%
-+ 0.00%
-+ 0.00%

EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026

Barchart·01/07/2026 06:00:00
Listen to the news

– Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets –

– Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 –

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.